Cost-effectiveness of lecanemab for early Alzheimer disease

XIONG Chaogang; WEI Junsong; AN Mengna; DENG Zijie; DU Lei; LEI Qian; ZHANG Xin; ZHANG Shengjie; MA Wenbing; FENG Weiyi

doi:10.6039/j.issn.1001-0408.2026.13.13

您当前的位置：

首页 >

文章列表页 >

Cost-effectiveness of lecanemab for early Alzheimer disease

更新时间：2026-07-10

- Cost-effectiveness of lecanemab for early Alzheimer disease
- ZHONGGUO YAOFANG Vol. 37, Issue 13, Pages: 1735-1739(2026)
- 作者机构：
  
  1.西安市胸科医院药剂科，西安　710100
  2.西安交通大学第一附属医院药学部，西安　710061
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.13.13
  CLC： R956
- Received：18 March 2026，
  
  Revised：2026-06-29，
  
  Accepted：29 June 2026，
  
  Published：15 July 2026
- 稿件说明：
移动端阅览
熊朝刚,魏俊松,安梦娜,等.仑卡奈单抗治疗早期阿尔茨海默病的药物经济学评价[J].中国药房,2026,37(13):1735-1739.

XIONG Chaogang,WEI Junsong,AN Mengna,et al.Cost-effectiveness of lecanemab for early Alzheimer disease[J].ZHONGGUO YAOFANG,2026,37(13):1735-1739.
熊朝刚,魏俊松,安梦娜,等.仑卡奈单抗治疗早期阿尔茨海默病的药物经济学评价[J].中国药房,2026,37(13):1735-1739. DOI： 10.6039/j.issn.1001-0408.2026.13.13.

XIONG Chaogang,WEI Junsong,AN Mengna,et al.Cost-effectiveness of lecanemab for early Alzheimer disease[J].ZHONGGUO YAOFANG,2026,37(13):1735-1739. DOI： 10.6039/j.issn.1001-0408.2026.13.13.

摘要

目的

从全社会角度出发，对仑卡奈单抗治疗早期阿尔茨海默病（AD）进行药物经济学评价。

方法

基于一项仑卡奈单抗治疗早期AD的全球多中心、随机、双盲、安慰剂对照研究（Clarity AD研究）的数据，根据AD的疾病发展进程建立Markov模型，循环周期为1个月，模拟至99%患者死亡。以质量调整生命年（QALY）和增量成本-效果比（ICER）为产出指标，以2倍我国2025年人均国内生产总值为意愿支付（WTP）阈值（199 330.00元/QALY），模拟在标准治疗（SoC）方案的基础上，仑卡奈单抗对比安慰剂治疗早期AD的经济性。采用单因素敏感性分析、概率敏感性分析和情境分析检验结果的稳健性。

结果

在SoC方案的基础上，仑卡奈单抗方案相比于安慰剂方案的ICER为4 364 711.54元/QALY。单因素敏感性分析结果显示，疾病进展风险比、仑卡奈单抗单价、体重、轻度认知障碍月进展概率及折现率为模型稳健性的关键影响参数。概率敏感性分析结果显示，在上述WTP阈值下，仑卡奈单抗联合SoC方案具有经济性的概率为0。情境分析结果显示，仑卡奈单抗单价需要至少降低94.88%才能低于设定的WTP阈值。

结论

在上述WTP阈值下，仑卡奈单抗联合SoC方案相较于安慰剂联合SoC方案治疗早期AD不具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of lecanemab for early Alzheimer disease （AD） from a whole-society perspective.

METHODS

Based on data from the Clarity AD study， a global multicenter， randomized， double-blind， placebo-controlled study of lecanemab for early AD， a Markov model was developed according to the disease progression of AD， with a monthly cycle and a time horizon extending to 99% patient mortality. Quality-adjusted life year （QALY） and incremental cost-effectiveness ratio （ICER） were used as outcome indicators， with a willingness-to-pay （WTP） threshold set at twice China’s per capita gross domestic product （GDP） for 2025 （199 330.00 yuan/QALY）. The model simulated the cost-effectiveness of lecanemab plus standard of care （SoC） versus placebo plus SoC for early AD. One-way sensitivity analysis， probabilistic sensitivity analysis， and scenario analysis were employed to test the robustness of the results.

RESULTS

Compared with placebo plus SoC， the ICER for lecanemab plus SoC was 4 364 711.54 yuan/QALY. One-way sensitivity analysis showed that the hazard ratio for disease progression， the price of lecanemab， body weight， the monthly progression probability of mild cognitive impairment， and the discount rate were key parameters affecting model robustness. Results of the probabilistic sensitivity analysis showed that the probability of lecanemab being cost-effective was 0 at the current WTP threshold. Scenario analysis indicated that a price reduction of at least 94.88% would be required for lecanemab to fall below the WTP threshold.

CONCLUSIONS

At the current WTP threshold， lecanemab plus SoC is not cost-effective compared with placebo plus SoC for early AD.

关键词

Keywords

references

Fu H S ， Huang H Q ， Liao S Z ， et al . Global burden of Alzheimer’s disease and other dementias （1990-2021）：inequality，frontier，and decomposition analysis [J ] . Front Aging Neurosci ， 2025 ， 17 ： 1637029 .

Fox J ， Mearns E S ， Li J ， et al . Indirect costs of Alzheimer’s disease：unpaid caregiver burden and patient productivity loss [J ] . Value Heal ， 2025 ， 28 （ 4 ）： 519 - 526 .

Gómez MaldonADo L ， de Mora-Figueroa R ， López-Angarita A ， et al . Cost of patients with Alzheimer’s di- sease in Spain according to disease severity [J ] . Pharmacoecon Open ， 2024 ， 8 （ 1 ）： 103 - 114 .

首都医科大学宣武医院国家神经疾病医学中心，中国疾病预防控制中心慢性非传染性疾病预防控制中心，国家卫生健康委能力建设和继续教育中心，等 . 中国阿尔茨海默病蓝皮书：精简版 [J ] . 中华医学杂志， 2024 ， 104 （ 29 ）： 2701 - 2727 .

Jr Jack C R ， Andrews J S ， Beach T G ， et al . Revised criteria for diagnosis and staging of Alzheimer’s disease： Alzheimer’s Association Workgroup [J ] . Alzheimers Dement ， 2024 ， 20 （ 8 ）： 5143 - 5169 .

van Dyck C H ， Swanson C J ， Aisen P ， et al . Lecanemab in early Alzheimer’s disease [J ] . N Engl J Med ， 2023 ， 388 （ 1 ）： 9 - 21 .

Chen C ， Katayama S ， Lee J H ， et al . Clarity AD：Asian regional analysis of a phase Ⅲ trial of lecanemab in early Alzheimer’s disease [J ] . J Prev Alzheimers Dis ， 2025 ， 12 （ 5 ）： 100160 .

Nguyen H V ， Mital S ， Knopman D S ， et al . Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease [J ] . Neurology ， 2024 ， 102 （ 7 ）： e209218 .

吴晶，刘国恩 . 中国药物经济学评价指南：2025中英双语版 [M ] . 北京：中国计划出版社， 2025 ： 53 .

Mitchell A J ， Shiri-Feshki M . Rate of progression of mild cognitive impairment to dementia：meta-analysis of 41 robust inception cohort studies [J ] . Acta Psychiatr Scand ， 2009 ， 119 （ 4 ）： 252 - 265 .

Spackman D E ， KADiyala S ， Neumann P J ， et al . Measuring Alzheimer disease progression with transition probabilities：estimates from NACC-UDS [J ] . Curr Alzheimer Res ， 2012 ， 9 （ 9 ）： 1050 - 1058 .

Stokes A C ， Weiss J ， Lundberg D J ， et al . Estimates of the association of dementia with US mortality levels using linked survey and mortality records [J ] . JAMA Neurol ， 2020 ， 77 （ 12 ）： 1543 - 1550 .

Villarejo A ， Benito-León J ， TrincADo R ， et al . Dementia-associated mortality at thirteen years in the NEDICES cohort study [J ] . J Alzheimers Dis ， 2011 ， 26 （ 3 ）： 543 - 551 .

国务院第七次全国人口普查领导小组办公室 . 2020中国人口普查年鉴 [EB/OL ] .（ 2021-05-11 ）[ 2026-01-03 ] . https：//www.stats.gov.cn/sj/pcsj/rkpc/7rp/zk/indexch.htm https://www.stats.gov.cn/sj/pcsj/rkpc/7rp/zk/indexch.htm .

Ren Y N ， Zhou D C ， Xing Q ， et al . Economic evaluation of the screening for Alzheimer’s disease in China [J ] . Front Aging Neurosci ， 2022 ， 14 ： 968842 .

Neumann P J ， Sandberg E A ， Araki S S ， et al . A comparison of HUI 2 and HUI 3 utility scores in Alzheimer’s disease [J ] . Med Decis Making ， 2000 ， 20 （ 4 ）： 413 - 422 .

Xia X ， Aye S ， Frisell O ， et al . The cost-effective price of lecanemab for patients with early Alzheimer’s disease in Sweden [J ] . Pharmacoeconomics ， 2025 ， 43 （ 10 ）： 1251 - 1266 .

Shin S ， Kim M ， Hong S H . Economic evaluation of lecanemab for early symptomatic Alzheimer’s disease in South Korea [J ] . Pharmacoecon Open ， 2025 ， 9 （ 5 ）： 793 - 804 .

Tan A R ， Wang Z X ， Aumont E ， et al . Determinants of treatment willingness and willingness-to-pay for leca- nemab in China：a network analysis [J ] . Alzheimer Dis Assoc Disord ， 2025 ， 39 （ 4 ）： 223 - 230 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of dilemmas and recommendations for value assessment of antitumor combination therapies

Long-term clinical effectiveness and cost-effectiveness of 10 first-line antiretroviral therapy regimens for HIV-infected patients in China

Pharmacoeconomic evaluation of culmerciclib combined with fulvestrant in the second-line treatment of HR+/HER2－ locally advanced or metastatic breast cancer

Pharmacoeconomic evaluation of zolbetuximab combined with chemotherapy as first-line treatment for CLDN18.2-positive and HER2-negative advanced gastric cancer

Rapid health technology assessment of lecanemab in the treatment of early-stage Alzheimer’s disease

Related Author

WANG Xuerong

ZHOU Ting

LI Yan

LI Hongchao

ZHOU Kejia

ZHOU Dachuang

TANG Wenxi

LIU Ran

Related Institution

School of International Pharmaceutical Business， China Pharmaceutical University

Research Center for Pharmacoeconomics Evaluation， China Pharmaceutical University

Dept. of Pharmacy， Hebei Medical University Third Hospital

School of Graduate， Hebei Medical University

Hebei Society for Integrated Drug and Health Technology Assessment

⁰